Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Escherichia coli K99 antigen, also known as F5 fimbriae, is a filamentous surface protein expressed by enterotoxigenic E. coli (ETEC) that serves as a critical virulence factor in neonatal livestock [1, 4]. It functions as an adhesin, mediating the attachment of the bacteria to specific glycolipid receptors, such as N-glycolyl-GM3, on the intestinal epithelial cells of calves, lambs, and piglets [17]. This attachment is the essential first step for bacterial colonization of the small intestine, which is followed by the release of enterotoxins that cause severe secretory diarrhea, dehydration, and high mortality [15, 16]. Because of its pivotal role in infection, the K99 antigen is a major target for veterinary vaccines and passive immunization products [6, 10]. Maternal vaccines are used to stimulate anti-K99 antibodies in the dam's colostrum, which, when ingested by the neonate, provide passive protection by blocking bacterial docking and preventing disease [7, 11]. Additionally, therapeutic monoclonal antibodies targeting the K99 antigen can be administered directly to newborns to provide immediate, short-term immunity [3, 12]. The efficacy of these interventions is often monitored by measuring anti-K99 antibody titers in the colostrum or the serum of the offspring [11]. Understanding the molecular interaction between K99 and its host receptors remains vital for developing next-generation multivalent vaccines against neonatal colibacillosis [10, 13].
Neutralization of bacterial adhesion by binding to the K99 fimbriae, thereby preventing the attachment of enterotoxigenic Escherichia coli to the intestinal epithelium and subsequent colonization.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Escherichia coli K99 antigen (K99).